Education is an important part of the MSG mission statement: Education - Championing excellence and innovation in the development and delivery of evidence-based medical knowledge in invasive fungal disease management for patients globally.  The MSGERC sets an annual educational agenda based on current evidence in mycology and collaborates with the Education Committee and educational consultants to organize a variety of shared learning activities that meet the learning needs of infectious disease specialists, adult and pediatric internists, pharmacists, health care practitioners, and researchers. MSGERC educational offerings may range from high-level international forums, “air lifted” educational conferences and symposia and enduring activities providing web-accessible continuing medical education. These programs are generally for practitioners aiming to provide the best prevention, diagnosis and treatment of invasive fungal infections in normal and immunocompromised patient populations.

ID in Motion

The YouTube channel “ID in Motion” is now online.

A first video has been posted and we will post more every ten days, five more videos are already shot, four cut, and we continue to tape more videos diligently.  Please take a look at

You can also follow @CornelyOliver via Twitter, where new videos will be announced every 10 days!

9th Advances Against Aspergillosis and Mucormycosis

Join many of the leading clinicians and scientists from around the world for the 9th Advances Against Aspergillosis and Mucormycosis conference, to take place in Lugano, Switzerland from 27th to 29th February 2020. This conference has now clearly established itself as the premier forum for detailed and dedicated discussion of all aspects of Aspergillus infection and research. Beginning with the 8th conference, we have expanded to now include scientific sessions on mucormycosis pathogenesis, diagnosis, and treatment.

The Aspergillus field continues in a state of rapid advancement, including the publication of numerous post-genomic papers and substantial advances in translational, immunologic, epidemiologic and diagnostic research. The mucormycosis field is similarly advancing with novel studies in pathogenesis and diagnostic options. The launch of several antifungals in the last few years and anticipated clinical trials of newer compounds with novel mechanisms of action is an exciting time for mycology. Pan-azole, and echinocandin Aspergillus resistance has emerged and requires unique approaches, and combination therapy remains an important area of interest for both aspergillosis and mucormycosis. Greatly increased awareness of allergic aspergillosis has opened new opportunities for both antifungal agents and immunotherapies. New molecular strategies for diagnosis continue to make progress, and recent guidelines offer increased diagnostic insight. There is a continuing high death toll from invasive aspergillosis and mucormycosis, including patient groups not usually associated with this opportunistic infection. This meeting is another chance to gather the world’s aspergillosis and mucormycosis experts in one venue. A fundamental tenet of this colloquium continues to be to engender collaborative relationships amongst clinicians, scientists, and industry to further advance the field.

Visit for more information or click here

The New Antifungal Toolkit 2019

We invite you to participate in the latest toolkit update: The New Antifungal Toolkit 2019: Review of Itraconazole Formulations and Application in Endemic Mycoses. In the first section, Dr Russell Lewis and Dr Dimitrios P. Kontoyiannia provide an overview of conventional itraconazole capsules as well as the IV formulation. They then review the profile of SUBA-itraconazole, an itraconazole formulation with enhanced bioavailability that recently became commercially available in the United States. In the second section, Dr George Thompson provides an update on endemic mycoses, including a discussion of the place for SUBA-itraconazole in therapy. We hope you find this toolkit helpful in your care of patients with invasive fungal infections who are candidates for itraconazole therapy.

Registration and Information

Learning Objectives
At the conclusion of this activity, the participants will be better able to:

  • Compare and contrast newly FDA-approved and emerging antifungal agents/formulations with established antifungal therapeutics
  • Evaluate factors affecting the bioavailability of antifungal agents and their impact on efficacy/safety
  • Provide appropriate treatment for endemic fungi

Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA, PhD Hon, FECMM, FAAM
Russell E. Lewis, PharmD, FCCP, BCPS
George R. Thompson III, MD, FACP

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Doctor Fungus Website

The DrFungus website was launched in the early 2000s and featured at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), December 2001.  The original website was spearheaded by Dr John Rex and a team of collaborators from 3 continents and a dedicated web designer.  Over the last decade, the site became dormant.  In 2016 MSGERC relaunched the website under a new design and branding.  With the initial sponsorship by Astellas, the site is publicly available at  This website features key updated encyclopedic features of the original site and includes Case of the Month.   To submit a case of the month, contact Peter G. Pappas, MD 

MSGERC Biennial Meeting

The MSGERC hosts a conference every two years whereby the fungal "state of the science" is presented by key opinion leaders in pre-clinical, veterinary, clinical areas.  The MSGERC Biennial Meeting provides an opportunity to generate new research concepts to address current and emerging unmet needs.  During this meeting academic investigators, junior investigators/fellows, private infectious disease practitioners, industry and government members join together for these common aims.  

MSGERC Education Initiatives

The Mycoses Study Group Education and Research Consortium (MSGERC) builds on its thirty-eight year legacy of scientific and academic expertise in mycology to collectively understand the needs of healthcare professionals in the field of mycology, institutions and companies worldwide. These include, but are not limited to the following:

  • Maintaining the desired level of expertise in a wide range of topics related to pre-clinical and clinical applications in mycology
  • Staying abreast of all cutting edge trends in mycology research for the prevention, diagnosis and disease management globally
  • Working endlessly to diagnose, treat and alleviate invasive fungal infections
  • Working to educate providers with state-of-the-art methods for treating invasive fungal infections

The MSGERC works with infectious disease key opinion leaders who have a broad range of expertise in a wide variety of patient populations, including oncology, rheumatology, pediatrics, HIV, and tropical medicine.  During its Biennial Meeting, the MSGERC invites key opinion leaders to present current pre-clinical, genomic, epidemiologic and clinical lectures addressing Endemic Mycoses, Cryptococcosis, Candidiasis, and Aspergillosis.  Each set of lectures is followed by facilitated discussions.  Video-taped lectures are featured on the MSGERC Youtube channel, Doctor Fungus website, and CDC Websites to disseminate information and learning opportunities.


The MSGERC works in tandem with key CME providers Terranova Medica, LLC  and University of Nebraska Center of Continuing Education, School of Medicine.

Many CMEs are currently available at the MSGERC Continuing Education Portal


The MSGERC has disseminated findings from its multiple studies and activities through presentations at meetings and publications in peer-reviewed journals and book chapters.  A list of MSG Publications can be accessed on the Scholarship page.

Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines 

Upcoming Meetings of Interest

For your convenience, we have listed upcoming meetings for 2019-20.  You may see some of our members on the agenda.





AAA – 9th Advances against Aspergillosis

Feb 27-29, 2020

Lugano, Switzerland

ASM Conference on Candida

April 19-23, 2020


ASM Microbe

June 18-22, 2020

Chicago, IL

FEBS State of the art course

Feb 16-23, 2020

Jena, Germany

Federation of Infection Societies

Nov 11-14, 2019

Edinburgh, Scotland, UK

ICHS- International Immunocompromised Host Society

Feb 13-14, 2020

Barcelona, Spain

ID Week

Oct 2-6, 2019

Washington DC


Nov 14-16, 2019

Salvador Bahia Brazil



International Conference on Cryptococcosis

June 1-5, 2020

Speke Resort, Munyonyo, Uganda


Sept 22-25, 2020 

Albuquerque, New Mexico


October 11-14, 2019

Nice France

Important Links

In addition to our long-standing commitment to generating educational outreach, MSG-member scholarly activities continue to contribute to awareness and education of mycology topics and treatment guidelines globally, including:


MSGERC Education Committee Members

George Thompson, MD, Chair (US)

John Baddley, MD, Co-Chair (US)

Ilan Schwartz- Co-Chair, Social Media (US)

Joe Vazquez- Co-Chair, Case of the Month (US)

Peter Pappas, MD- Co-Chair, Biennial Meeting, Patient Advocacy

Other Members:

Barbara Alexander, MD (US)

David Andes, MD (US)

David Boulware (US)

Oliver Cornely, MD (DRG)

Dimitrios Kontoyiannis, MD (US)

Bart-Jan Kullberg, MD (NL)

Luis Ostrosky-Zeichner, MD (US)

Tom Patterson, MD (US)

John Perfect, MD (US)

Marisa Micheli, MD (US)

Monica Slavin, MD (AU)

Carolynn Thomas Jones, DNP, MSPH, RN, (MSGERC Executive Director) (US)

Alisa Peinhardt, MAIS, RN (MSGERC Clinical Operations Director) (US)

Lisa Tushla, PhD (Educational Consultant)

Tom Davis (Educational Consultant)

Last Updated 9/9/19

(412) 344-2437

MSGERC Privacy Policy   

Powered by Wild Apricot Membership Software